$39.97
0.67% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US40131M1099
Symbol
GH

Guardant Health, Inc. Target price 2025 - Analyst rating & recommendation

Guardant Health, Inc. Classifications & Recommendation:

Buy
85%
Hold
11%
Sell
4%

Guardant Health, Inc. Price Target

Target Price $58.86
Price $39.97
Potential
Number of Estimates 22
22 Analysts have issued a price target Guardant Health, Inc. 2026 . The average Guardant Health, Inc. target price is $58.86. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 27 analysts: 23 Analysts recommend Guardant Health, Inc. to buy, 3 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Guardant Health, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 739.02 885.12
31.04% 19.77%
EBITDA Margin -54.29% -25.42%
41.33% 53.18%
Net Margin -59.56% -38.78%
36.53% 34.89%

23 Analysts have issued a sales forecast Guardant Health, Inc. 2025 . The average Guardant Health, Inc. sales estimate is

$885m
Unlock
. This is
14.36% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$890m 15.00%
Unlock
, the lowest is
$855m 10.47%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $739m 31.04%
2025
$885m 19.77%
Unlock
2026
$1.1b 21.21%
Unlock
2027
$1.3b 22.78%
Unlock
2028
$1.6b 23.11%
Unlock
2029
$1.7b 3.83%
Unlock

18 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2025. The average Guardant Health, Inc. EBITDA estimate is

$-225m
Unlock
. This is
45.52% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-135m 67.21%
Unlock
, the lowest is
$-248m 39.97%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-401m 23.12%
2025
$-225m 43.93%
Unlock
2026
$-159m 29.17%
Unlock
2027
$-64.3m 59.65%
Unlock
2028
$6.8m 110.54%
Unlock
2029
$17.0m 150.74%
Unlock

EBITDA Margin

2024 -54.29% 41.33%
2025
-25.42% 53.18%
Unlock
2026
-14.85% 41.58%
Unlock
2027
-4.88% 67.14%
Unlock
2028
0.42% 108.61%
Unlock
2029
1.01% 140.48%
Unlock

20 Guardant Health, Inc. Analysts have issued a net profit forecast 2025. The average Guardant Health, Inc. net profit estimate is

$-343m
Unlock
. This is
17.88% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-239m 42.90%
Unlock
, the lowest is
$-428m 2.37%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-440m 16.82%
2025
$-343m 22.03%
Unlock
2026
$-295m 13.98%
Unlock
2027
$-228m 22.70%
Unlock
2028
$-184m 19.35%
Unlock
2029
$-115m 37.32%
Unlock

Net Margin

2024 -59.56% 36.53%
2025
-38.78% 34.89%
Unlock
2026
-27.52% 29.04%
Unlock
2027
-17.33% 37.03%
Unlock
2028
-11.35% 34.51%
Unlock
2029
-6.85% 39.65%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.56 -2.78
16.82% 21.91%
P/E negative
EV/Sales 6.28

20 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. EPS is

$-2.78
Unlock
. This is
17.75% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.93 42.90%
Unlock
, the lowest is
$-3.46 2.37%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.56 16.82%
2025
$-2.78 21.91%
Unlock
2026
$-2.39 14.03%
Unlock
2027
$-1.85 22.59%
Unlock
2028
$-1.49 19.46%
Unlock
2029
$-0.93 37.58%
Unlock

P/E ratio

Current -11.83 83.13%
2025
-14.40 21.72%
Unlock
2026
-16.74 16.25%
Unlock
2027
-21.66 29.39%
Unlock
2028
-26.85 23.96%
Unlock
2029
-42.84 59.55%
Unlock

Based on analysts' sales estimates for 2025, the Guardant Health, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.18 30.55%
2025
6.28 12.52%
Unlock
2026
5.18 17.50%
Unlock
2027
4.22 18.55%
Unlock
2028
3.43 18.77%
Unlock
2029
3.30 3.69%
Unlock

P/S ratio

Current 6.40 24.46%
2025
5.59 12.55%
Unlock
2026
4.62 17.50%
Unlock
2027
3.76 18.55%
Unlock
2028
3.05 18.77%
Unlock
2029
2.94 3.69%
Unlock

Current Guardant Health, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Piper Sandler
Locked
Locked
Locked May 06 2025
Scotiabank
Locked
Locked
Locked May 05 2025
Stifel
Locked
Locked
Locked May 01 2025
Barclays
Locked
Locked
Locked May 01 2025
TD Securities
Locked
Locked
Locked May 01 2025
Canaccord Genuity
Locked
Locked
Locked May 01 2025
UBS
Locked
Locked
Locked May 01 2025
Analyst Rating Date
Locked
Piper Sandler:
Locked
Locked
May 06 2025
Locked
Scotiabank:
Locked
Locked
May 05 2025
Locked
Stifel:
Locked
Locked
May 01 2025
Locked
Barclays:
Locked
Locked
May 01 2025
Locked
TD Securities:
Locked
Locked
May 01 2025
Locked
Canaccord Genuity:
Locked
Locked
May 01 2025
Locked
UBS:
Locked
Locked
May 01 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today